Condition
Neuroendocrine Tumor Grade 2 clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Neuroendocrine Tumor Grade 2 clinical trials that are recruiting, at sites in 4 countries (most in United States (2), Brazil (1), Italy (1)). By phase: Phase 2 (3), Phase 2/3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest Neuroendocrine Tumor Grade 2 clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Investigating the impact of somatostatin analogues on tumor dose during radionuclide therapy | Phase 2/3 | Amsterdam | Recruiting | Mar 3, 2025 |
| Comparing two doses of Everolimus for treating neuroendocrine tumors | Phase 2 | São Paulo, São Paulo and 1 other locations | Recruiting | Jun 25, 2024 |
| Customized Lutetium-177 treatment for neuroendocrine tumors | Phase 2 | Iowa City, Iowa | Recruiting | May 2, 2024 |
| Exploring new biomarkers for diagnosing and treating neuroendocrine tumors | — | Rome, Italy | Recruiting | Jul 9, 2020 |
| Combination therapy for Grade 2 liver-dominant neuroendocrine tumors | Phase 2 | La Jolla, California and 4 other locations | Recruiting | Apr 8, 2020 |
All recruiting trials (5)
-
Investigating the impact of somatostatin analogues on tumor dose during radionuclide therapy
This study is testing if stopping or continuing long-acting somatostatin treatment affects how well radionuclide therapy works for adults with neuroendocrine tumors.
-
Comparing two doses of Everolimus for treating neuroendocrine tumors
This study is testing whether a lower dose of Everolimus can effectively treat patients with advanced neuroendocrine tumors while causing fewer side effects compared to a higher dose.
-
Customized Lutetium-177 treatment for neuroendocrine tumors
This study is testing if a personalized dose of Lutetium-177 can improve treatment results for adults with hard-to-treat neuroendocrine tumors compared to standard treatment.
-
Exploring new biomarkers for diagnosing and treating neuroendocrine tumors
This study is testing new ways to diagnose and treat neuroendocrine tumors by looking at blood samples to see if they can provide better information about the cancer.
-
Combination therapy for Grade 2 liver-dominant neuroendocrine tumors
This study is testing a new combination treatment of two drugs followed by a special radiation therapy to see if it helps people with Grade 2 liver-dominant neuroendocrine tumors live longer without their cancer getting worse.
Related topics
Quick answers
How many Neuroendocrine Tumor Grade 2 clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (2 trials), Brazil (1 trial), Italy (1 trial), Netherlands (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.